• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Design Therapeutics, Inc. - Common Stock (NQ:DSGN)

10.05 -0.31 (-2.99%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Design Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Design Therapeutics to Participate in Upcoming Investor Conferences
November 26, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
November 05, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
September 10, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
August 27, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
August 07, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
June 04, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
May 28, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
May 13, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
May 07, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
May 01, 2025
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
April 21, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
April 17, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Leerink’s Global Healthcare Conference
March 03, 2025
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
November 13, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
November 07, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
August 05, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 12, 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 13, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 09, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
April 24, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
From Design Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap